MBI’s Oralex finishes phase II trials
Ultrasound contrast agent developer Molecular Biosystems has completed phase II clinical trials of its Oralex oral ultrasound contrast agent, which is targeted for the improvement of abdominal ultrasound images. Preliminary data evaluation of the
Ultrasound contrast agent developer Molecular Biosystems has completed phase II clinical trials of its Oralex oral ultrasound contrast agent, which is targeted for the improvement of abdominal ultrasound images. Preliminary data evaluation of the 59-patient study found that Oralex provided significant diagnostic utility when compared with noncontrast and water-contrast imaging, according to MBI.
Oralex works by distending the stomach and displacing bowel gas to provide physicians with a better view of the upper gastrointestinal anatomy, including the stomach wall and pancreas. The San Diego-based firm believes that Oralex provides significant benefit over the current method of improving ultrasound images, which involves ingestion of water.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
